Microsponge A Novel New Drug Delivery System: A Review by Charde, Manoj et al.
       International Journal of Advances in Pharmaceutics  2 (6) 2013     
Review Article
Microsponge A Novel New Drug Delivery System: A Review
M. S. Charde*, P. B. Ghanawat, A. S. Welankiwar, J. Kumar and R. D. Chakole
Government College of Pharmacy, KathoraNaka, Amravati-444604, (M.S.) India – 444604
*Correspondence Info:
Government College of Pharmacy,
Amravati, MS India 444604
Email: manojudps@rediffmail.com
 
  
Keywords: 
Microsponge,
control release,
target release,
topical,
over-the counter (OTC)
1. Introduction
Microsponges  are  polymeric  delivery  systems  composed  of  porous  microspheres.  They  are tiny  sponge-like
spherical particles with a large porous surface. Moreover, they may enhance stability, reduce side effects and modify drug
release favorably. Microsponge technology has many favourable characteristics, which make it a versatile drug delivery
vehicle.  Microsponge Systems are based on microscopic, polymer-based microspheres that can suspend or entrap a wide
variety of substances, and can then be incorporated into a formulated product such as a gel, cream, liquid or powder. MDS
can provide increased efficacy for topically active agents with enhanced safety, extended product stability and improved
aesthetic properties in an efficient manner [1, 2, 3]. To control the delivery rate of active agents to a predetermined site in the
human body has been one of the biggest challenges faced by Pharmaceutical scientists. Several predictable and reliable
systems have been developed for systemic delivery of drugs under the heading of transdermal delivery system (TDS) using
the skin as portal of entry. It has improved the efficacy and safety of many drugs that may be better administered through
skin. But TDS is not practicable for delivery of materials whose final target is skin itself. Controlled release of drugs onto
the epidermis  with assurance that  the drug remains primarily localized and  does not  enter  the systemic  circulation in
significant amounts is a challenging area of research[4]. Microsponges consist of non-collapsible structures with porous
surface through which active ingredients are released in controlled manner. Depending upon the size, the total pore length
may range up to 10 ft. and pore volume up to 1 ml/g. When applied to the skin, the microsponge drug delivery system
(MDS) releases its active ingredient on a time mode and also in response to other stimuli such as rubbing, temperature, and
pH Microsponges have the capacity to adsorb or load a high degree of active materials into the particle or onto its surface.
Its  large  capacity for  entrapment  of  actives  up to  3  times  its  weight  differentiates  microsponges  from other  types  of
dermatological delivery systems. Mostly microsponge is use for transdermal drug delivery system [5, 6].
Defining Microsponge:  The Microsponge Delivery System (MDS) is a patented polymeric system consisting of porous
microspheres. They are tiny sponge like spherical particles that consist of a myriad of interconnecting voids within a non-
collapsible structure with a large porous surface through which active ingredient are released in a controlled manner. The
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size of the microsponges ranges from 5-300µm in diameter and a typical 25µm sphere can have up to 250000 pores and an
internal pore structure equivalent to 10 feet in length, providing a total pore volume of about 1ml/g for extensive drug
retention. The surface can be varied from 20 to 500 m /g and 2 pore volume range from 0.1 to 0.3cm /g. This results in a
large reservoir within each 3 microsponge, which can be loaded with up to its own  weight of active agent  [7, 8, 9]. The
microsponge technology was developed by Won in 1987, and the original patents were assigned to Advanced Polymer
Systems, Inc. This company developed a large number of variations of the procedures and those are applied to the cosmetic
as well as over-the- counter (OTC) and prescription pharmaceutical products  [7, 10]. At the current time, this interesting
technology has been licensed to Cardinal Health, Inc., for use in topical products. The scanning electron microscopy of the
microsponge particle reveals that its internal structure as the “bag of marbles”. The porosity is due to the interstitial spaces
between the marbles. The interstitial pores can entrap many wide range of active ingredients such as emollients, fragrances,
essential oils, sunscreens, anti-infective and anti-inflammatory agents. These entrapped microsponges may then integrated
or formulated into product forms, such as creams, lotions, powders, soaps, capsules and tablets. When these products are
applied the entrapped material gets delivered to the skin in a controlled time release pattern or a pre-programmed manner
through the use of several different ‘triggers’, rubbing or pressing the Microsponge after it has been applied to the skin,
elevates  skin  surface  temperature  introducing  solvents  for  the  entrapped  materials  such  as  water,  alcohol  or  even
perspiration and controlling the rate of evaporation. Active ingredients entrapped in the porous polymeric structure display
altered behaviour, with respect to their release, which is restricted and prolonged [7, 11].
Potential features or characteristic of microsponge drug delivery systems:
1. Microsponges show acceptable stability over pH ranging from 1 to 11 and at high temperatures (up to130°C).
2. Microsponges exhibit good compatibility with various vehicles and ingredients.
3. Microsponges have high entrapment efficiency up to 50 to 60%.
4. Microsponges are characterized by free flowing properties.
5. The average pore size of microsponges is small (0.25 µm) in a way to prevent the penetration of bacteria, thus they do not
need sterilization or addition of preservatives.
6. Microsponges are non-allergenic, non-irritating, non-mutagenic and non-toxic.
7. Microsponges can absorb oil up to 6 times their weight without drying [12, 13, 14, 15].
Benefit of microsponge drug delivery system:
1. Enhanced product performance.
2. Extended release.
3. Reduced irritation and hence improved patient Compliance.
4. Improved product elegancy.
5. Improved oil control as it can absorb oil up to 6 times its weight without drying. 
6. Improved formulation flexibility.
7. Improved thermal, physical, and chemical stability.
8. Flexibility to develop novel product forms. 
9. Microsponge systems are non-irritating, non-mutagenic, non-allergenic and non-toxic [4, 16].
Characteristics of actives moieties that is entrapped into microsponges:
1. Active ingredients that are entrapped in microsponge can then be incorporated into many products such as creams, gels,
powders, lotions and soaps.
2. Certain  considerations  are  taken  into  account  while,  formulating  the  vehicle  in  order  to  achieve  desired  product
characteristics:
3. It should be either fully miscible in monomer as well as capable of being made miscible by addition of small amount of a
water immiscible solvent.
4. It should be inert to monomers and should not increase the viscosity of the mixture during formulation.
5. It should be water immiscible or nearly only slightly soluble.
6. It should not collapse spherical structure of the microsponges.
7. It should be stable in contact with polymerization catalyst and also in conditions of polymerization.
8. The solubility of actives in the vehicle must be limited.
9. If not, the vehicles will deplete the microsponges before the application.
10. Not more than 10 to 12% w/w microsponges must be incorporated into the vehicle in order to avoid cosmetic problems.
11. Payload and polymer design of the microsponges for the active must be optimized for required release rate for given
period of time [17, 18]
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Structure of microsponge:
Drug enclosed in microsponge drug delivery system [19-23]:
• Ketoprofen
• Benzyl peroxide
• Retinol
• Fluconazole
• Ibuprofen
• Tretinoin
• Trolamine
2. Method of preparation of microsponge
Micro sponge’s drug delivery system can be prepared in two ways, one-step process or by two-step process that is
liquid-liquid suspension polymerization and quasi emulsion solvent diffusion techniques based that is based on physico-
chemical properties of drug to be loaded. 
1. Liquid-liquid suspension polymerization 
The  porous  microspheres  are  prepared  by suspension polymerization method in  liquid-liquid systems.  In  this
method the monomers which are immiscible are first dissolved along with active ingredients in a suitable solvent monomer
and are then dispersed in the aqueous phases which consist of additives like surfactant, suspending agents to facilitate
formation of suspension. The polymerization is then activated by increasing temperature or irradiation or by addition of
catalyst. The polymerization process continues the formation of a reservoir type of system with spherical structure. After the
polymerization process the solvent is removed leaving the spherical structured porous microspheres, i.e., microsponges [1,
24-26].
2. Quasi-emulsion solvent diffusion:
Porous microspheres (microsponges) were also prepared by a quasi-emulsion solvent diffusion method (two-step
process) using an internal phase containing polymer such as eudragit which is dissolved in ethyl alcohol. Then, the drug is
slowly added to the polymer solution and dissolved under ultra-sonication at 35oC and plasticizer such as triethylcitrate
(TEC) was added in order to aid the plasticity. The inner phase is then poured into external phase containing polyvinyl
alcohol  and  distilled  water  with  continuous  stirring  for  2  hours.  Then,  the  11  mixture  was  filtered  to  separate  the
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microsponges. The product (microsponges) was washed and dried in an air- heated oven at 40°C for 12 hr. [17, 27].
 
Drug release mechanism of microsponge:  The active ingredient is added to the vehicle in an entrapped form. As the
microsponge particles have an open structure (they do not have a continuous membrane surrounding them), the active is free
to move in and out from the particles and into the vehicle until equilibrium is reached, when the vehicle becomes saturated.
Once the finished product is applied to the skin, the active that is already in the vehicle will be absorbed into the skin,
depleting the vehicle, which will become unsaturated, therefore, disturbing the equilibrium. This will start a flow of the
active from the microsponge particle into the vehicle, and from it to the skin, until the vehicle is either dried or absorbed.
Even after that the microsponge particles retained on the surface of the stratum corneum will continue to gradually release
the active to the skin, providing prolonged release over time. This proposed mechanism of action highlights the importance
of formulating vehicles for use with microsponge entrapments. If the active is too soluble in the desired vehicle during
compounding of the finished products, the products will not provide the desired benefits of gradual release. Instead they will
behave as if the active was added to the vehicle in a free form. Therefore, while formulating microsponge entrapments, it is
important  to  design  a  vehicle  that  has  minimal  solubilizing  power  for  the  actives.  This  principle  is  contrary  to  the
conventional  formulation principles  usually applied to  topical  products.  For  these  conventional  systems it  is  normally
recommended to maximize the solubility of the active in the vehicle [7, 28].
Accelerated or Triggered by following mechanism [29, 30]:
(і)Pressure triggered systems
Microsponge releases the entrapped material when pressurized/rubbed.
(іі)Temperature triggered systems
It is possible to modulate the release of substances from the microsponge by modulation of temperature. That is viscous
sunscreens were show a higher release when exposed to higher temperatures.
(ііі)pH triggered systems
Triggering the pH-based release of the active can be achieved by modifying the coating on the microsponge. 
(іv)Solubility triggered system
Microsponges loaded with water-soluble ingredients will release the ingredient in the presence of water. Perspiration can
trigger the release rate of active ingredients [29, 30].
Advantages over Conventional Formulations:  Conventional formulations of topical drugs are intended to work on the
outer layers of the skin. Such products release their active ingredients upon application, producing a highly concentrated
layer  of  active ingredient  that  is  rapidly absorbed.  When compared to the Microsponge system can prevent  excessive
accumulation  of  ingredients  within  the  epidermis  and  the  dermis.  Potentially,  the  Microsponge  system  can  reduce
significantly the irritation of effective drugs without reducing their efficacy. For example, by delivering the active ingredient
gradually to the skin like MDS Benzoyl peroxide formulations have excellent efficacy with minimal irritation [31-34].
Advantages  over  Microencapsulation  and  Liposomes:  The  MDS  has  advantages  over  other  technologies  like
microencapsulation and liposomes.  Microcapsules  cannot  usually control  the  release rate  of  actives.  Once the  Wall  is
ruptured.  The actives  contained within microcapsules  will  be released.  Liposomes suffer  from lower payload,  difficult
formulation, limited chemical stability and microbial instability. While microsponge system in contrast to the above systems
are stable over range of  pH 1 to 11, temperature up to 130  0C ; compatible with most vehicles and ingredients; self-
sterilizing as average  pore size is 0.25 µm where bacteria cannot penetrate;  higher payload (50 to 60%),  still free  flowing
and can  be cost effective [31-34].
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Evaluation of Microsponge:
(i) Particle size determination: - Particle size analysis of loaded and unloaded microsponges can be performed by laser light
diffractometry or any other suitable method. The values can be expressed for all formulations,  size range. Cumulative
percentage drug release from microsponges of different particle size will be plotted against time to study effect of particle
size on drug release. Particles larger than PMµm can impart gritty feeling and hence particles of sizes between NM and
25µm are preferred to use in final topical formulation. 
(ii) Morphology and surface topography of microsponges:-Prepared microsponges can be coated with gold–palladium under
an argon atmosphere at room temperature and then the surface morphology of the microsponges can be studied by scanning
electron microscopy (SEM). SEM of a fractured microsponge particle can also be taken to illustrate its ultra-structure.
(iii) Determination of loading efficiency and production yield: - The loading efficiency (%) of the microsponges can be
calculated according to the following equation: Loading efficiency = Actual Drug Content in Microsponges X 100…….. (1)
Theoretical Drug Content: The production yield of the micro particles can be determined by calculating accurately the initial
weight of the raw materials and the last weight of the microsponge obtained.
Production Yield= Practical mass of
Microsponges X 100……… (2)
Theoretical mass (Polymer+drug).
(iv)  Characterization of pore structure:-Pore volume and diameter are vital  in controlling the intensity and duration of
effectiveness of the active ingredient. Pore diameter also affects the migration of active ingredients from microsponges into
the vehicle in which the material is dispersed. Mercury intrusion porosimetry can be employed to study effect  of pore
diameter and volume with rate of drug release from microsponges. Porosity parameters of microsponges such as intrusion–
extrusion isotherms pore size distribution, total pore surface area, average pore diameters, interstitial void volume, percent
porosity, percent porosity filled, shape and morphology of the pores, bulk and apparent density can be determined by using
mercury intrusion porosimetry. 
(v) Dissolution tests:-Dissolution release rate of microsponges can be studied by use of dissolution apparatus USP XXIII
with  a  modified  basket  consisted  of  5µm stainless  steel  mesh.  The dissolution medium is  selected  while  considering
solubility of actives to ensure sink conditions. At various intervals the samples from the dissolution medium was analysed
by suitable analytical methods.
(vi) Determination of true density:-The true density of micro particles is measured using an ultra-pycnometer under helium
gas and is calculated from a mean of repeated determinations
(vii) Resiliency (viscoelastic properties):- Resiliency (visco elastic properties) of microsponges can be modified to produce
beadlets that is softer or firmer according to the needs of the final formulation. Increased cross-linking tends to slow down
the rate of release [35-41]. 
Applications of microsponges: Microsponge delivery systems are used to enhance the safety, effectiveness and aesthetic
quality  of  topical  prescription,  over-the-counter  and  personal  care  products.  Microsponges  can  be  used  in  variety of
applications. It is used mostly for topical and recently for oral administration. Several patents have reported that it can be
used as an excipient  due to its  high loading capacity and sustained release ability.  It  offers  the formulator a range of
alternatives to develop drug and cosmetic products. Microsponges are designed to deliver a pharmaceutical active ingredient
efficiently at the minimum dose and also to enhance stability, reduce side effects and modify drug release. Over-the-counter
products  that  incorporate  microsponge  drug  delivery  system  include  numerous  moisturizers,  specialized  rejuvenated
products, and sunscreens [42].
1. Microsponge for topical delivery
The Microsponge systems are based on microscopic, polymer-based microspheres that can bind, suspend or entrap
a wide variety of substances and then be incorporated into a formulated product, such as a gel, cream, liquid or powder. A
single Microsponge is as tiny as a particle of talcum powder, measuring less than one-thousandth of an inch in diameter.
Like a true sponge, each microsphere consists of a myriad of interconnecting voids within a non-collapsible structure that
can accept a wide variety of substances. The outer surface is typically porous, allowing the controlled flow of substances
into and out of the sphere. Several primary characteristics, or parameters, of the Microsponge system can be defined during
the  production  phase  to  obtain  spheres  that  are  tailored  to  specific  product  applications  and  vehicle  compatibility.
Microsponge systems are made of biologically inert polymers. Extensive safety studies have demonstrated that the polymers
are non-irritating, non- mutagenic, non-allergenic, non-toxic and non-biodegradable. As a result, the human body cannot
convert them into other substances or break them down. Although they are microscopic in size, these systems are too large
to pass through the stratum corneum when incorporated into topical products. Benzoyl peroxide (BPO) is commonly used in
topical formulations for the treatment of acne, with skin irritation as a common side effect. It has been shown that controlled
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release of BPO from a delivery system to the skin could reduce the side effect while reducing percutaneous absorption.
Therefore, microsponge delivery of Benzoyl peroxide was developed using an emulsion solvent diffusion method by adding
an organic internal phase containing benzoyl peroxide, ethyl cellulose and dichloromethane into a stirred aqueous phase
containing polyvinyl alcohol and by suspension polymerization of styrene and  divinyl benzene. The prepared microsponges
were dispersed in gel base and microsponge gels are evaluated for anti-bacterial and skin irritancy. The entrapped system
released the drug at slower rate than the system containing free BPO. Topical delivery system with reduced irritancy was
successfully developed [41-49].
2. Microsponge for oral delivery
In oral applications, the microsponge system has been shown to increase the rate of solubilisation of poorly water-
soluble drugs by entrapping such drugs in the microsponge system's pores. As these pores are very small, the drug is in
effect reduced to microscopic particles and the significant increase in the surface area thus greatly increases the rate of
solubilisation. Controlled oral delivery of ibuprofen microsponges is achieved with an acrylic polymer, Eudragit RS, by
changing  their  intraparticle  density.  Sustained  release  formulation  of  chlorpheniramine  maleate,  using  powder-coated
microsponges, is prepared by the dry impact blending method, for oral drug delivery. Controlled oral delivery of Ketoprofen
prepared by quasi-emulsion solvent diffusion method with Eudragit RS 100 and afterwards tablets of microsponges were
prepared by the direct  compression method. Results indicated that  compressibility was much improved in the physical
mixture of  the drug and polymer;  due to  the plastic  deformation of  the sponge-like microsponge structure,  producing
mechanically strong tablets.  Colon-specific,  controlled delivery of  Flurbiprofen was conducted by using a commercial
Microsponge 5640 system. In vitro studies exhibited that compression-coated colon-specific tablet formulations started to
release the drug at  the eighth hour,  corresponding to the proximal  colon arrival  time, due to  addition of  the enzyme,
following a modified release pattern, while the drug release from the colon-specific formulations prepared by pore plugging
the microsponges showed an increase at  the eighth hour,  which was the point of time when the enzyme addition was
made[41-49].
3. Microsponge for Bone and Tissue Engineering Bone-substitute 
Compounds were obtained by mixing pre polymerized powders of polymethyl methacrylate and liquid methyl methacrylate
monomer with two  aqueous dispersions of tricalcium phosphate grains and calcium deficient hydroxyapatite powders. The
final composites appeared to be porous and acted as microsponges. Basic fibroblast growth factor (bFGF) incorporated in a
collagen sponge sheet was sustained released in the mouse sub-cutis according to the biodegradation of the sponge matrix,
and exhibited local angiogenic activity in a dose-dependent manner. The injection of collagen microsponges incorporating
bFGF induced a significant increase in the blood flow, in the murine ischemic hind limb, which could never have been
attained by the bolus injection of bFGF. These results suggest the significance and therapeutic utility of the type I collagen
as a reservoir of bFGF [41-49]. 
Recent advances in microsponge drug delivery system: Various advances were made by modifying the methods to form
Nan sponges, nanoferrosponges and porous micro beads. β - CD nanosponges were also developed that can be used for
hydrophobic as well as hydrophilic drugs, in contrast to polymeric micro or nanosponges. These advanced systems were
studied for oral administration of dexamethasone, Flurbiprofen, doxorubicin hydrochloride, itraconazole and serum albumin
as model drug. These nanosponges were developed by cross- linking the β CD molecule by reacting the β-CD with biphenyl
carbonate. Some researchers also observed the nanosponges as good carrier for the delivery of gases. Researchers also
observed that incorporating a cytotoxic in a nanosponge carrier system can increase the potency of the drug suggesting that
these carriers can be potentially used for targeting the cancerous cells [50].
3. Conclusion
The microsponge delivery technology of controlled release system in which active pharmaceutical ingredient is
loaded in the macro porous beads and initiates reduction in side effects with improved therapeutic efficacy. Microsponge
can be effectively incorporated into topical drug delivery system for retention of dosage form on skin, and also use for oral
delivery of drugs using bio erodible polymers, especially for colon specific delivery and controlled release drug delivery
system thus improving patient compliance by providing site specific drug delivery system and prolonging dosage intervals.
This technology is being used currently in cosmetics, over-the-counter skin care, sunscreens, and prescription products. This
kind  of  drug  delivery  technology may lead  to  a  better  understanding  of  the  healing  of  several  diseases.  Hence,  the
microsponge-based drug delivery technology is likely to become a valuable drug delivery matrix substance for various
therapeutic applications in the future.
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